Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.